R&D Trends

Immunocore, MedImmune collaborate on immuno-oncology combination trials

Friday, April 17, 2015 12:36 PM

Immunocore, a biotechnology company developing novel biological drugs to treat cancer and other diseases headquartered outside Oxford, England, and MedImmune, the global biologics R&D arm of AstraZeneca, have entered into a second collaboration.

More... »

Quest Diagnostics

Veracyte, GE collaborate to improve disease diagnosis

Wednesday, April 15, 2015 12:54 PM

Veracyte, a South San Francisco, Calif.-based molecular diagnostic company pioneering the field of molecular cytology, and GE, focused on software, advanced manufacturing, energy and healthcare, have formed a research collaboration to develop new solutions that can improve disease diagnosis. Financial and other terms have not been disclosed.

More... »


Study: 2014 a record-setting year for U.S. medicines

Wednesday, April 15, 2015 12:44 PM

Total spending on U.S. medicines increased 10.3% on a real per capita basis to $373.9 billion in 2014, with a record volume of 4.3 billion prescriptions filled. The year also marked the highest number of transformative medicines launched in more than a decade, according to a new report issued by the IMS Institute for Healthcare Informatics. IMS Health is a global information and technology services company based in Parsippany, N.J.

More... »

HHS to award $1M in new grant programs to improve sharing of health information

Wednesday, April 15, 2015 12:37 PM

Health and Human Services has made available $1 million in grant funds to support community projects for the Community Interoperability Health Information Exchange (HIE) Program. The funding will help support and enable the flow of health information at the community level, leading to better care and better health.

More... »

NIH, South African Medical Research Council award $8M in HIV, TB grants

Monday, April 13, 2015 12:23 PM

The NIH and the South African Medical Research Council (SAMRC) are awarding 31 grants to U.S. and South African scientists to support research targeting HIV/AIDS, tuberculosis and HIV-related co-morbidities and cancers.

More... »

Medivir, Cancer Research Technology collaborate to develop new class of cancer drugs

Monday, April 13, 2015 12:15 PM

Medivir, a research-based pharmaceutical company based in Sweden, and Cancer Research Technology (CRT), Cancer Research U.K.’s commercialization and development arm, have partnered to develop a new class of drugs that has shown promise for treating a range of different cancers, including pancreatic cancer.

More... »

BioXcel, Takeda partner to repurpose assets for orphan diseases

Friday, April 10, 2015 01:45 PM

BioXcel, a Branford, Conn.-based provider of cloud-based pharma big data solutions for discovering novel products, has partnered with Takeda Development Center Americas for the repurposing of assets across the gamut of rare diseases.

More... »

NIH funds nine antimicrobial resistance diagnostics projects

Friday, April 10, 2015 01:31 PM

The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has awarded more than $11 million in first-year funding for nine research projects supporting enhanced diagnostics to rapidly detect antimicrobial-resistant bacteria. The awardee institutions will develop tools to identify certain pathogens that frequently cause infections in health care settings and, specifically, those that are resistant to most antimicrobials. Advancing the development of rapid and innovative diagnostic tests for identifying and characterizing resistant bacteria is a key goal of the President’s recent National Action Plan for Combating Antibiotic-Resistant Bacteria.

More... »

Pfizer launches competitive grants program for cardiovascular disease research

Friday, April 10, 2015 01:21 PM

Pfizer has launched a new competitive grants program to support research projects investigating the role of Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) in health and cardiovascular disease. This competitive grants program, which is an extension of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Cardiovascular program, is part of Pfizer's ongoing commitment to translate scientific discoveries into innovative medicines for patients with cardiovascular disease.

More... »

Sanford-Burnham, Daiichi Sankyo ink agreement

Thursday, April 9, 2015 01:48 PM

Sanford-Burnham Medical Research Institute, a nonprofit, independent institute that employs more than 1,000 scientists and staff in San Diego, Calif., and Orlando, Fla., has signed a licensing agreement to further develop a first-in-class small molecule with Daiichi Sankyo for the treatment of cardiovascular-metabolic disease.

More... »

CWWeekly

April 13

Quintiles-Quest Diagnostics joint venture latest in CRO-central lab deals, more could be on horizon

Biotech companies raise record amount of capital in Q1

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs